Tramadol for the treatment of fibromyalgia

References

• Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013;17(8):356-013. 0356-5
   PubMed Web of Science ®Google Scholar
• Bellato E, Marini E, Castoldi F, et al. Fibromyalgia syndrome: Etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012;2012:426130
   PubMedGoogle Scholar
• Russell IJ, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6(5):250-7
   PubMed Web of Science ®Google Scholar
• Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
   PubMed Web of Science ®Google Scholar
• Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009;36(10):2318-29
   PubMed Web of Science ®Google Scholar
• Bernik M, Sampaio TP, Gandarela L. Fibromyalgia comorbid with anxiety disorders and depression: combined medical and psychological treatment. Curr Pain Headache Rep 2013;17(9):358-013 -0358-3
   PubMed Web of Science ®Google Scholar
• Nicassio PM, Radojevic V, Schoenfeld-Smith K, Dwyer K. The contribution of family cohesion and the pain-coping process to depressive symptoms in fibromyalgia. Ann Behav Med 1995;17(4):349-56
   PubMed Web of Science ®Google Scholar
• Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med 2004;66(6):837-44
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. report of the multicenter criteria committee. Arthritis Rheum 1990;33(2):160-72
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62(5):600-10
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Faregh N, Ste-Marie PA, Shir Y. Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res Treat 2013;2013:898493
   PubMedGoogle Scholar
• Bennett RM, Friend R, Marcus D, et al. Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary American College of Rheumatology criteria and the development of alternative criteria. Arthritis Care Res 2014;66(9):1364-73
   PubMed Web of Science ®Google Scholar
• Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. Am J Health Syst Pharm 2011;68(14):1307-19
   PubMed Web of Science ®Google Scholar
• Hauser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 2014;16(1):201
   PubMed Web of Science ®Google Scholar
• Kalso E. How different is oxycodone from morphine? Pain 2007;132(3):227-8
   PubMed Web of Science ®Google Scholar
• Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014:6:CD010692
   Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67(4):536-41
   PubMed Web of Science ®Google Scholar
• Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain 2010;14(1):5-10
   PubMed Web of Science ®Google Scholar
• American Pain Society. Guideline for the Management of Pain in Fibromyalgia. American Pain Society Clinical Practice Guidelines Program. Available from: www.ampainsoc.org [Last accessed 2 November 2014]
   Google Scholar
• Fitzcharles MA, Ste-Marie PA, Gamsa A, et al. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med 2011;124(10):955-60
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011;14(2):145-61
   PubMed Web of Science ®Google Scholar
• Wasserman RA, Brummett CM, Goesling J, et al. Characteristics of chronic pain patients who take opioids and persistently report high pain intensity. Reg Anesth Pain Med 2014;39(1):13-17
   PubMed Web of Science ®Google Scholar
• Brummett CM, Janda AM, Schueller CM, et al. Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, observational cohort study. Anesthesiology 2013;119(6):1434-43
   PubMed Web of Science ®Google Scholar
• Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 2004;5:48
   PubMed Web of Science ®Google Scholar
• Harris RE, Clauw DJ, Scott DJ, et al. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007;27(37):10000-6
   PubMed Web of Science ®Google Scholar
• Peng X, Robinson RL, Mease P, et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain 2015;31(1):7-13
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Ryan K, Chandran A, Zlateva G. “What is the true cost of fibromyalgia to our society: results from a cross-sectional survey in the United States.” Arthritis and Rheumatism 2009;60(Suppl 10):104
   Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105-20
   PubMed Web of Science ®Google Scholar
• Mika J, Zychowska M, Makuch W, et al. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacological Rep 2013;65(6):1611-21
   PubMed Web of Science ®Google Scholar
• Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ’atypical’ opioid analgesic. J Pharmacol Exp Ther 1992;260(1):275-85
   PubMed Web of Science ®Google Scholar
• Frink MC, Hennies HH, Englberger W, et al. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 1996;46(11):1029-36
   PubMed Web of Science ®Google Scholar
• Kaneko K, Umehara M, Homan T, et al. The analgesic effect of tramadol in animal models of neuropathic pain and fibromyalgia. Neurosci Lett 2014;562:28-33
   PubMed Web of Science ®Google Scholar
• Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998;18(1):13-19
   PubMedGoogle Scholar
• Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114(7):537-45
   PubMed Web of Science ®Google Scholar
• Bennett RM, Schein J, Kosinski MR, et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005;53(4):519-27
   PubMedGoogle Scholar
• Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheumatic Dis 2011;14(1):6-11
   PubMed Web of Science ®Google Scholar
• Yokotsuka S, Kato J. Tramadol/acetaminophen combination tablets. Masui the Japanese Journal of Anesthesiology 2013;62(7):791-8
   PubMedGoogle Scholar
• Tzschentke TM, Christoph T, Schroder W, et al. Tapentadol: With two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. preclinical overview. [Tapentadol: mit zwei Mechanismen in einem Molekul wirksam gegen nozizeptive und neuropathische Schmerzen. Praklinischer Uberblick]. Schmerz Berlin, Germany 2011;25(1):19-25
   PubMed Web of Science ®Google Scholar
• Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009;25(5):1095-104
   PubMed Web of Science ®Google Scholar
• Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative [bunionectomy] pain. Curr Med Res Opin 2009;25(3):765-76
   PubMed Web of Science ®Google Scholar
• Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136(3):432-44
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36(2):398-409
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med Malden, Mass 2000;1(4):310-16
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(4):1264-73
   PubMed Web of Science ®Google Scholar
• Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11(6):505-21
   PubMed Web of Science ®Google Scholar
• Bernstein CD, Albrecht KL, Marcus DA. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opin Pharmacother 2013;14(7):905-16
   PubMed Web of Science ®Google Scholar
• Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60(6):636-44
   PubMed Web of Science ®Google Scholar
• Paris BL, Ogilvie BW, Scheinkoenig JA, et al. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 2009;37(10):2045-54
   PubMed Web of Science ®Google Scholar
• Kim SH, Song J, Mun H, Park KU. Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia. Korean J Intern Med 2009;24(2):139-42
   PubMedGoogle Scholar